Clinical utility of oncofetal proteins and hormones as tumor markers (Q38169153)

30 August 2017

1 reference

title

Clinical utility of oncofetal proteins and hormones as tumor markers (English)

1 reference

30 August 2017

Garrett PE

1

1 reference

30 August 2017

Kurtz SR

series ordinal

2

1 reference

30 August 2017

publication date

1 November 1986

1 reference

Medical Clinics of North America

30 August 2017

published in

1 reference

30 August 2017

volume

70

1 reference

30 August 2017

issue

6

1 reference

30 August 2017

page(s)

1295-1306

1 reference

Value of β-subunit of human chorionic gonadotropin, pregnancy-specific β1-glycoprotein, and α-fetoprotein in preoperative evaluation of patients with a pelvic mass

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930899-9

7 January 2021

Prolactin response to thyrotropin-releasing hormone (TRH) in patients with hypothalamic-pituitary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930899-9

7 January 2021

Demonstration of a new protein fraction in serum from the human fetus

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930899-9

7 January 2021

Prolactin stimulation of maternal behavior in female rats

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930899-9

7 January 2021

Testicular carcinoma. A curable malignancy

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930899-9

7 January 2021

DEMONSTRATION OF TUMOR-SPECIFIC ANTIGENS IN HUMAN COLONIC CARCINOMATA BY IMMUNOLOGICAL TOLERANCE AND ABSORPTION TECHNIQUES

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930899-9

7 January 2021

Carcinoembryonic Antigen: Its Role as a Marker in the Management of Cancer. A National Institutes of Health Consensus Development Conference

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930899-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930899-9

1 reference

7 January 2021

Two CEA and three NCA species, although distinguishable by monoclonal antibodies, have nearly identical peptide patterns

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930899-9

7 January 2021

Decreased bone density in hyperprolactinemic women

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930899-9

7 January 2021

A Graphical Method to Analyze Serum Tumor Marker Decay in Nonseminomatous Testis Tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930899-9

7 January 2021

CEA-directed second-look surgery in the asymptomatic patient after primary resection of colorectal carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930899-9

7 January 2021

Tumour Markers in Testicular Germ Cell Tumours Five-Year Experience from the DATECA Study 1976–1980

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930899-9

7 January 2021

Justification of the use of surveillance in the management of Stage I germ cell tumours of the testis

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930899-9

7 January 2021

Prognostic Significance of a Decline in Serum Human Chorionic Gonadotropin Levels After Initial Chemotherapy for Advanced Germ-Cell Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930899-9

7 January 2021

Metabolism of HCG in man

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930899-9

7 January 2021

Bone density in amenorrheic women with and without hyperprolactinemia

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930899-9

7 January 2021

Diagnostic applications of alpha-fetoprotein: government regulations prevent full application of a clinically useful test

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930899-9

7 January 2021

Recurrence of hyperprolactinemia after selective transsphenoidal adenomectomy in women with prolactinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930899-9

7 January 2021

Human chorionic gonadotropin levels in complete and partial hydatidiform moles and in nonmolar abortuses

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930899-9

7 January 2021

Evolution of the genes for the beta subunits of human chorionic gonadotropin and luteinizing hormone

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930899-9

7 January 2021

A radioimmunoassay which specifically measures human chorionic gonadotropin in the presence of human luteinizing hormone

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930899-9

7 January 2021

Effect rates of different modalities for treatment of prolactin adenomas

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930899-9

7 January 2021

Monoclonal versus polyclonal antibody radioimmunoassay against the beta-subunit of human chorionic gonadotropin in patients with gestational trophoblastic neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930899-9

7 January 2021

10.1016/S0025-7125(16)30899-9

Identifiers

DOI

0 references

1 reference